TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04729179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Participants will start with 10 mg of cannabidiol daily and the dose will be escalated every third day until the maximum dosage of 50 mg is reached (after two weeks). The participants be on the 50 mg dosage of cannabidiol for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as tablets of 10 mg that are identical in appearance, taste, and smell to the Cannabidiol tablets.The participants will be on the 50 mg dosage of placebo for 24 weeks.
Study: NCT05436379

Intervention type: DEVICE
Group type: OTHER
Intervention: Theta Burst Stimulation
Description: TBS, a next-gen form of transcranial magnetic stimulation (TMS), requires shorter duration and frequency of stimulation and provides comparable clinical efficacy to traditional repetitive TMS for depression. Thus it is an appropriate technique for use with young adults with depression. TBS can be delivered safely and effectively on an accelerated schedule with two sessions/day. Based on an earlier (ongoing) study of TBS to dorsomedial prefrontal cortex, investigators will administer TBS to dmPFC over 2 weeks in young adults with depression. Addressing the behavioral aspects of anhedonia and reward processing, a subset of participants will also receive positive affect training. Magnetic resonance imaging will guide the personalized location of TBS and will be used to examine change in frontostriatal circuitry with TBS. This study has the potential to influence development of new treatments for depression and anhedonia, with possible mechanisms in frontostriatal brain function.
Study: NCT06155578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical 25% sodium metabisulfite (SM) in pediatric cold cream
Description: Topical 25% sodium metabisulfite (SM) in pediatric cold cream will be applied twice daily on hand calcinosis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pediatric cold cream will be applied twice daily on hand calcinosis.
Study: NCT06125743

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Participants will conduct self-care activities prescribed by their treating lymphedema therapists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person LEF-SMP
Description: Participants will receive the in-person LEF-SMP intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth LEF-SMP
Description: Participants will receive the telehealth LEF-SMP intervention.
Study: NCT06445387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: Preparation Stage of Virtual Glasses: A 20-minute video consisting of nature scenes shot with a 360-degree camera was selected by the researchers from YouTube. Permission was obtained from the person who created the video.~For the selection of music, both the music that is good for diseases were examined in the literature and an expert opinion was taken from a faculty member (Phd, assistant professor) working at the Faculty of Music and Fine Arts of a university. The music used in the video was created with works selected from the Hüseyni maqam.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice Application Group
Description: Features of the ice and ice bag used for patients in ice application; Ice cubes with dimensions of 9.5 x 26 x 3.5 cm were used. The ice bag is made of cotton and polyester coated fabric and is easily bendable. In this way, the ice bag was ensured to fit properly to the patient's femoral region. It is reusable and heat insulated. The procedure was carried out by following the cold application step protocol created by the researchers using the literature.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: They continued to receive their routine treatment and care. No changes were made in their routine treatment and care.
Study: NCT04861870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MenCare+/Bandebereho fathers'/couples' group education
Description: MenCare+/Bandebereho was a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants were first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engaged men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focused on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
Study: NCT05310201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be Well Care Well
Description: Be Well Care Well addresses teacher well-being through activities implemented in the classroom aimed at reducing teacher stress and improving physical activity. A subset of teachers involved in the program will complete classroom observations and cortisol testing to examine additional measures of stress.
Study: NCT05250713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial stimulation
Description: Patients will receive either direct current stimulation or alternate stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial stimulation
Description: Patients will receive either direct current stimulation or alternate stimulation.
Study: NCT04661475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: ECT and anaesthetic treatment protocols will be determined by the local ECT services. ECT being given twice a week. The anesthetic induction agent of choice will usually be propofol, with thiopental permissible as an alternative. For safety reasons, any drug contraindicated to be given with DEX will be avoided. Especially the once known to decrease arterial pressure and heart rate excessively. Oral psychotropic medication to be continued by the patient's treating clinical team will remain unchanged where possible for at least the first 4 ECT treatments, and ideally until end of ECT. Eligible subjects will be allocated randomly to receive either 0.5µg/kg dexmedetomidine add on (diluted to 10 ml with 0.9% saline) at a steady rate of 1 ml/min, for 10 min.Participants in the two groups will receive DEX or Saline adjunct thrice weekly for 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: while patients in the Control group will be infused with 10 ml of 0.9% saline at the same rate, over 10 minutes before anesthesia induction for ECT procedure.
Study: NCT05461105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rencofilstat, 75 mg
Description: 1 softgel capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rencofilstat, 150mg
Description: 2 softgel capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rencofilstat, 225 mg
Description: 3 softgel capsules
Study: NCT05430048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nasal Desmopressin
Description: compare the effect of nasal desmopressin versus oral bisoprolol for controlling bleeding and improving surgical field clarity during functional endoscopic sinus surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nasal Desmopressin
Description: compare the effect of nasal desmopressin versus oral bisoprolol for controlling bleeding and improving surgical field clarity during functional endoscopic sinus surgery.
Study: NCT05697549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavior language therapy
Description: Cognitive behavior language therapy is an extensive form of Cognitive behavior therapy. and it is used in the management of speech-language related problems. It helps the individuals to change their unhelpful thoughts and beliefs that cause difficulty for them to communicate properly and effectively. and it also helps the individuals to use their remaining language abilities, to restore their language abilities and to learn the other ways of communication i.e. pointing, gesturing and Augmentative alternative communication.
Study: NCT05449886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVC
Description: Tidal volume challenge from 6ml/kg to 10ml/kg for 1 min.
Study: NCT05591625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitisation and Reprocessing
Description: EMDR is a trauma-focussed, psychological talking therapy whereby the participant verbally relates a narrative of an emotionally disturbing memory, in brief sequential doses, while simultaneously focusing on an external stimulus, most commonly side-to-side finger movements of the psychological therapist. EMDR aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR is widely practiced, so is scalable. It is also protocolised, so can be taught and tested, and allows for fidelity assessment in controlled studies.~The number of sessions will depend on ongoing presence of disturbing memories. This will be determined by the psychological therapist and participant.
Study: NCT05145842

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: floroscopy
Description: After proper antiseptic dressing and draping, sacral hiatus was identified. the position of the needle was confirmed by lateral and anteroposterior fluoroscopic images. The needle was introduced up to S3 level for proper spread of the drug.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound+fluoroscopy
Description: After proper antiseptic dressing and draping, the caudal region will be shown in the longitudinal section using sterile probe cover and gel. Under ultrasonographic imaging, the sacrococcygeal ligament will be crossed and the needle will not be advanced any further once the sacral canal is entered. The fluoroscopy phase of the combined imaging will be started and the needle position will be checked by taking an anteroposterior view. The needle tip will be positioned at the sacral 3 level. The needle will be repositioned until the proper position is achieved. The research will be terminated at this point and the time to this stage and the radiation exposure dose will be obtained.
Study: NCT03669653

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days.
Study: NCT05208853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti CD30 CAR-T Cell Injection
Description: After enrollment, subjects complete the apheresis, then complete the lymphodepletion, and then receive the dose escalation test: 1.5×10\^7 cells，1.5×10\^8 cells，5× 10\^8 cells.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion
Study: NCT06124742

Intervention type: DEVICE
Intervention: clear aligners
Description: taste perception will be evaluated before and after using clear aligners.
Study: NCT05174923

Intervention type: BEHAVIORAL
Intervention: Short Performance Physical Battery (SPPB Test)
Description: The SPPB includes balance stands, a 4-meter walk and 5 timed chair stands.

Intervention type: BEHAVIORAL
Intervention: Short Performance Physical Battery (SPPB Test)
Description: The SPPB includes balance stands, a 4-meter walk and 5 timed chair stands.

Intervention type: BEHAVIORAL
Intervention: Short Performance Physical Battery (SPPB Test)
Description: The SPPB includes balance stands, a 4-meter walk and 5 timed chair stands.

Intervention type: BEHAVIORAL
Intervention: 30 Second Chair Stand Test (30CST)
Description: The 30CST measures the number of times a person can rise from a seated to standing position within 30 seconds.

Intervention type: BEHAVIORAL
Intervention: 30 Second Chair Stand Test (30CST)
Description: The 30CST measures the number of times a person can rise from a seated to standing position within 30 seconds.

Intervention type: BEHAVIORAL
Intervention: 30 Second Chair Stand Test (30CST)
Description: The 30CST measures the number of times a person can rise from a seated to standing position within 30 seconds.

Intervention type: BEHAVIORAL
Intervention: Hand grip dynamometry
Description: Grip strength is used as a marker of overall muscle strength.

Intervention type: BEHAVIORAL
Intervention: Hand grip dynamometry
Description: Grip strength is used as a marker of overall muscle strength.

Intervention type: BEHAVIORAL
Intervention: Hand grip dynamometry
Description: Grip strength is used as a marker of overall muscle strength.
Study: NCT05262088

Intervention type: OTHER
Intervention: video recording of general movements
Description: Video recording of general movements of children aged 3-5 days, then 4-5, 8-9, 12-13, 16-17, 20-22 weeks of life.~At the age of 12 weeks of life, an assessment will be made on the Motor Optimality Scale (MOS).
Study: NCT06280495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 5 mg/m2 IV on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 5 mg/m2 IV on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 400 mg/m2 IV bolus on day 1, followed by 2.4 g/m2 continuous IV infusion over 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 400 mg/m2 IV bolus on day 1, followed by 2.4 g/m2 continuous IV infusion over 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: 200 mg IV infusion on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg IV infusion on day 1
Study: NCT05453916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500Mg Oral Tablet
Description: patients receiving treatment with Nitazoxanide 500 mg two times daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin 550Mg Tab
Description: patients receiving treatment rifaximin at a dose of 550 mg three times daily for 14 days
Study: NCT04762225

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPTR-168
Description: Escalating doses of RPTR-168 as a monotherapy
Study: NCT05309538

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified eply & Semont maneuver
Description: repositioning maneauvers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: betahistine & Modified eply & Semont maneuver
Description: antihistamine plus repositioning maneuvers
Study: NCT06037174

Intervention type: PROCEDURE
Intervention: minimally invasive procedure
Description: different minimally invasive approach to complete thyroidectomy, including endoscopy-assisted subclavian approach, robot-assisted transaxillary or transoral approach (not leaving scar on the neck)

Intervention type: PROCEDURE
Intervention: Conventional Open Surgery
Description: Conventional Open Surgery
Study: NCT06257355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSB-001 Ophthalmic Solution 0.1%
Description: CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSB-001 Ophthalmic Solution 0.1%
Description: CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
Study: NCT03529448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TN-TC11G
Description: TN-TC11G dose will be gradually increased as follows:~Week 1: TN-TC11G: 0-0-5 mg (THC 5 mg + CBD 5 mg; in the mornings, 90 minutes after breakfast; in the afternoons, 90 minutes after lunch; in the evenings, 90 minutes after dinner).~Week 2: TN-TC11G: 5-0-5 mg Week 3: TN-TC11G: 5-5-5 mg Week 4: TN-TC11G: 5-5-10 mg Week 5: TN-TC11G: 5-5-15 mg Week 6: TN-TC11G: 10-10-15 mg Week 7: TN-TC11G: 10-10-20 mg. Week 8: TN-TC11G: 15-15-30 mg Week 9: TN-TC11G: 20-20-40 mg TN-TC11G will be administered daily at the relevant dose level according to the individual titration performed in the first 9 weeks of treatment. If there is any dose reduction, the reduced dose must be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide Oral Product
Description: During RT, patients will receive Temozolomide (TMZ). All patients will be given TMZ at 75 mg/m2/d concurrently with RT for a maximum of 42 days.~At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All the patients will receive the Stupp regimen. The radiotherapy (RT) treatment will be administered in fractions of 1.8-2.0 Gy/day delivered 5 days/week to a total dose of 58-60 Gy. Radiotherapy will be delivered to the gross tumor volume with a 2-3 cm margin for the clinical target volume.
Study: NCT05084222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buventol® Easyhaler® 200 µg/inhalation dmDPI
Description: Two doses will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI
Description: Two doses will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ventoline® Evohaler® 100 µg/inhalation pMDI
Description: Four doses will be administered via Volumatic spacer
Study: NCT05688098

Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine High
Description: Co-administration of Irbesartan and Amlodipine High
Study: NCT04685109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alocross 0.2% Unit Dose
Description: Eye Drops
Study: NCT06196125

Intervention type: OTHER
Intervention: Four body positions
Description: Physiological characteristics such as ventilation distribution and lung aeration patterns recorded by the electrical impedance tomography signals and ultrasound imaging will be measured when patients are in a initial supine position, then turned into a lateral positioning on each side then back in supine positioning.
Study: NCT04685109

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vismed
Description: Eye drops
Study: NCT06189118

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Mindfulness Based Cognitive Therapy or Health Education Program
Description: 12 hours of online group training of Mindfulness Based Cognitive Therapy OR 12 hours of online group training of Health Education Program will be provided via teleconferencing. Additional both groups will perform daily home practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness Based Cognitive Therapy or Health Education Program
Description: 12 hours of online group training of Mindfulness Based Cognitive Therapy OR 12 hours of online group training of Health Education Program will be provided via teleconferencing. Additional both groups will perform daily home practice.
Study: NCT04284839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOAC
Description: Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VKA
Description: Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
Study: NCT05899660

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Omega-3
Description: It is a dietary supplement made of fish oil rich in n-3 PUFA.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: olive oil
Description: Refined olive oil is the usual placebo used in studies with n-3 PUFA.
Study: NCT04939636

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 capsules 4000IU/100µg.
Description: Vitamin D3 supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 capsules 600IU/15µg.
Description: Vitamin D3 supplementation
Study: NCT05989373

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Scratch collapse test
Description: Scratch test performed by the surgeon but with a dynamometer
Study: NCT05420441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonophoresis with chitosan
Description: Patients in this group will receive chitosan through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonophoresis with glucoasmine
Description: Patients in this group will receive glucosamine through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: Patients in the control group will receive the conventional treatment for knee osteoarthritis only, which will include the application of TENS, pulsed ultrasound, infrared light and exercise.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: Patients in the control group will receive the conventional treatment for knee osteoarthritis only, which will include the application of TENS, pulsed ultrasound, infrared light and exercise.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Patients in the control group will receive the conventional treatment for knee osteoarthritis only, which will include the application of TENS, pulsed ultrasound, infrared light and exercise.